Late-clinical-stage biotech firm Electra Therapeutics is pushing forward with its U.S. initial public offering, aiming for a market valuation of up to $977.6 million as health-sector listings rebound.
📌 Key Takeaways & Important Metrics:
- Capital Target: Seeking to raise up to $346.7 million by offering 21.67 million shares priced between $14 and $16 per share.
- Lead Drug Candidate: Proceeds will fund ongoing clinical trials for ipsoprubart, an experimental therapy targeting severe overactive immune system conditions (secondary HLH), alongside advancing candidate ELA822.
- Listing Details: Plans to list on Nasdaq under the ticker symbol “ETRA”.
- Underwriting Syndicate: Bookrunners include Jefferies, TD Cowen, Evercore ISI, and Cantor.
💥 The Big Picture: Despite broader macroeconomic caution, Electra’s multi-hundred-million-dollar debut underscores persistent investor appetite for late-stage immunology and oncology innovations.